Company News
3/2024 - Published online a study in collaboration with Georgetown University that describes the elevation of plasma astrocyte-derived extracellular vesicles (ADE) in the first month post ischemic stroke in humans and a potential relationship to hemorrhagic transformation.
In a study published online in Nature.com. (2024) 14:5272 investigators demonstrate that plasma ADE levels measured by EAAT-1/CD9 co-expression are significantly elevated when tested at 5, 15, and 30 days post ischemic stroke as compared to matched controls tested over that same time period. ADEs were also increased at 15 days post stroke in ischemic patients with hemorrhagic transformation when compared to those without transformation. This indicates that plasma ADE levels preferentially increased over the first month post stroke may reflect trophic support of astrocytes to injured neurons following ischemia and/or potentially further disruption of the blood brain barrier with hemorrhagic transformation in ischemic stroke.
12/26/2023 - NanoSomiX announces Issuance of its 4th U.S. patent expanding its proprietary exosome isolation and biomarker detection technology.
U.S. Patent No. 11,852,635 B2, titled “Quantification of Subpopulations of Exosomes and Diagnosis of Neurodegenerative Disorders” covers simultaneous detection of double positive exosomes expressing one or more exosome biomarkers including CD81, CD63, CD9 where in exosomes are positive for one or more neural biomarkers selected from the group of CD171, SNAP25, EAAT1, and OMGP and also can bind at least one or more markers related to receptors including those for dopamine, serotonin, glutamate, adrenalin, nor adrenalin and others. This patent includes neuron, astrocyte, oligodendrocyte and microglia derived exosomes and provides broad coverage of NSX technology for assessment of extracellular vesicles (EV) with neurologic etiology as well as the measurement of such EV in biologic fluids applicable to a variety of neurologic conditions.
5/18/2018 - NanoSomiX, Inc. Announces Issuance of First US Patent
NanoSomiX, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the company’s first patent covering its groundbreaking proprietary exosome isolation and biomarker detection technology.
4/12/2018 - Published study shows biomarker promise for neurotrauma recovery monitoring
NanoSomiX has further expanded its diagnostic applications which utilize its patented Brain Derived Exosome technology. A recently published study in Frontiers in Neurology tested a unique panel of blood biomarkers using this enhanced approach to evaluate the recovery process after sport-related neurotrauma.
6/16/2015 – Specialized Proteins May Be Detected in Blood of People with Alzheimer's Disease
Specialized brain proteins that are involved in the removal of damaged nerve cell materials may be detected in the blood of people who were diagnosed with mild cognitive impairment or dementia due to Alzheimer’s disease. In a select group of people who later developed dementia, the levels of the lysosomal proteins were abnormal while the people still had no problems with memory or thinking skills, according to a study published in the June 10, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
11/17/2014 - Research on Blood Test for Brain Insulin Resistance Is Featured at Society for Neuroscience Conference
A new blood test that detects brain insulin resistance, as an abnormality associated with Alzheimer’s disease, was featured by meeting organizers as a “Hot Topic” presentation at the recent annual meeting of the Society for Neuroscience (SFN). The conference, held here in Washington Nov. 15-19, is the world’s largest meeting on brain science.
10/30/2014 - Study Says Blood Test for Brain Insulin Resistance Accurately Predicts Alzheimer's Disease Risk
Brain insulin resistance is an abnormality in Alzheimer’s disease that contributes to neural cell damage and can be detected by a new blood test, according to a multi-site study that was published October 23 in the online issue of The FASEB Journal, The Journal of the Federation of American Societies for Experimental Biology. The highly statistically significant findings were made possible by a novel technique the researchers developed for measuring brain insulin resistance in living patients.
9/10/2014 - NanoSomiX Announces New Blood Test for Use by Alzheimer's Disease Researchers
A new blood test reliably predicts whether a person is likely to develop Alzheimer's Disease (AD) up to 10 years before the disease is diagnosed, according to a multi-site study recently published in the Alzheimer's Association journal Alzheimer's & Dementia.
7/16/2014 – Research presented at AAIC in Copenhagen, Denmark
The technology that is the foundation for the blood-based p-tau assay under development at NanoSomiX was presented at the 2014 Alzheimer's Association International Conference (AAIC) in Copenhagen. The presentation was one of five subjects chosen to be highlighted in the Developing Topics Oral Session, one of the most anticipated sessions at the conference due to its focus on the latest advancements. Dr. Dimitrios Kapogiannis from the National Institute on Aging, National Institutes of Health (NIA/NIH) presented the findings in his talk titled Pathogenic Proteins in Neurally-Derived Blood Exosomes as Near-Perfect Diagnostic and Prognostic Biomarkers for Alzheimer's Disease.
A summary of the presentation appears in an article in Alzforum titled Exosomes Stand Out as Potential Blood Biomarkers: http://www.alzforum.org/news/conference-coverage/exosomes-stand-out-potential-blood-biomarkers